An ANDA is the FDA pathway that lets generic drug makers prove their products are identical to brand-name drugs - without repeating costly clinical trials. It's why 90% of U.S. prescriptions are filled with generics that cost 80-85% less.
The first generic drug manufacturer to launch after a patent expires captures up to 80% of the market - and keeps a dominant share for years. Here’s how the Hatch-Waxman Act creates lasting advantage, why big players win, and what’s changing in 2026.
Medications